Pluvicto Prostate Cancer Trial: Phase III Results

By João L. Carapinha

June 3, 2025

Novartis recently announced the topline results from the Phase III Pluvicto prostate cancer trial. The addition of Pluvictoâ„¢ (lutetium (177Lu) vipivotide tetraxetan) to standard hormone therapy significantly improved radiographic progression-free ...
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
Alzheimer’s Blood Test Diagnostics: FDA Clears First Blood Test for Ear...
EMA AI Tool Qualification: How the AIM-NASH Approval Sets a Roadmap for Medic...
VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options
First At-Home HPV Testing Approval: FDA Clears Teal Wand
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...
Nipocalimab for Myasthenia Gravis Treatment